158 related articles for article (PubMed ID: 16317313)
1. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia.
Kane JM; Khanna S; Rajadhyaksha S; Giller E
Int Clin Psychopharmacol; 2006 Jan; 21(1):21-8. PubMed ID: 16317313
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
4. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
Zimbroff D; Warrington L; Loebel A; Yang R; Siu C
Int Clin Psychopharmacol; 2007 Nov; 22(6):363-70. PubMed ID: 17917555
[TBL] [Abstract][Full Text] [Related]
7. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study.
Addington DE; Labelle A; Kulkarni J; Johnson G; Loebel A; Mandel FS
Can J Psychiatry; 2009 Jan; 54(1):46-54. PubMed ID: 19175979
[TBL] [Abstract][Full Text] [Related]
8. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.
Hirsch SR; Kissling W; Bäuml J; Power A; O'Connor R
J Clin Psychiatry; 2002 Jun; 63(6):516-23. PubMed ID: 12088164
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
Zhao T; Park TW; Yang JC; Huang GB; Kim MG; Lee KH; Chung YC
Int Clin Psychopharmacol; 2012 Jul; 27(4):184-90. PubMed ID: 22426471
[TBL] [Abstract][Full Text] [Related]
10. Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.
Lawson WB; Herman BK; Loebel A; Lazariciu I; Malik M
CNS Spectr; 2009 Sep; 14(9):478-86. PubMed ID: 19890230
[TBL] [Abstract][Full Text] [Related]
11. Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study.
Loebel AD; Khanna S; Rajadhyaksha S; Siu CO; Giller E; Potkin SG
J Clin Psychiatry; 2007 Sep; 68(9):1333-8. PubMed ID: 17915970
[TBL] [Abstract][Full Text] [Related]
12. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
Potkin SG; Weiden PJ; Loebel AD; Warrington LE; Watsky EJ; Siu CO
Int J Neuropsychopharmacol; 2009 Oct; 12(9):1233-48. PubMed ID: 19419595
[TBL] [Abstract][Full Text] [Related]
13. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
14. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.
Grootens KP; van Veelen NM; Peuskens J; Sabbe BG; Thys E; Buitelaar JK; Verkes RJ; Kahn RS
Schizophr Bull; 2011 Mar; 37(2):352-61. PubMed ID: 19542525
[TBL] [Abstract][Full Text] [Related]
15. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
16. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial.
Potkin SG; Keck PE; Segal S; Ice K; English P
J Clin Psychopharmacol; 2005 Aug; 25(4):301-10. PubMed ID: 16012271
[TBL] [Abstract][Full Text] [Related]
17. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study.
Brook S; Walden J; Benattia I; Siu CO; Romano SJ
Psychopharmacology (Berl); 2005 Apr; 178(4):514-23. PubMed ID: 15650846
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
[TBL] [Abstract][Full Text] [Related]
19. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
[TBL] [Abstract][Full Text] [Related]
20. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
Sacchetti E; Galluzzo A; Valsecchi P; Romeo F; Gorini B; Warrington L;
Schizophr Res; 2009 May; 110(1-3):80-9. PubMed ID: 19269791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
